Overview
- Ionis and AstraZeneca announced on July 9, 2026 that CARDIO‑TTRansform did not meet its primary composite endpoint of cardiovascular death and recurrent cardiovascular events through Week 140 versus placebo.
- A prespecified monotherapy subgroup showed a nominally significant reduction in the primary composite outcome with eplontersen versus placebo, with a reported hazard ratio of 0.71.
- Most trial participants were on TTR stabilizer therapy at baseline and an additional share started stabilizers during the study, and no treatment effect was seen in patients receiving stabilizers at baseline.
- Secondary clinical, imaging, and biomarker measures favored eplontersen, including large and sustained reductions in transthyretin levels, and the drug’s safety profile was described as consistent with prior data.
- Sponsors will continue full data review and present detailed findings at ESC in August 2026, a step that could shape how silencer drugs are used alongside stabilizers and influence regulatory and clinical decisions that affect patient care.